



November 6, 2020

BSE Limited

Corporate Relationship Department Phiroze Jeeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001. Scrip Code: 512529

Dear Sir/ Madam,

National Stock Exchange of India Limited

Listing Department Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051. Symbol: SEQUENT

Sub: Change in Directorship

Pursuant to Regulation 30 (read with Part A of Schedule III) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, *inter-alia*, has approved the appointment of Mr. Gregory John Andrews (DIN: 08904518) as an Additional Director (Non-Executive Non-Independent) of the Company w.e.f. November 6, 2020 to hold office as such until the conclusion of ensuing Annual General Meeting of the Company.

Mr. Gregory John Andrews has been nominated by CA Harbor Investments (Part of The Carlyle Group) as their nominee on the Board of the Company.

Brief profile and other Information of Mr. Gregory John Andrews pursuant to SEBI Circular bearing reference CIR/CFD/CMD/4/2015 dated September 9, 2015 is given in the enclosed as an 'Annexure A'.

We request you to take the above on record.

Thanking you,

Yours faithfully,

For Sequent Scientific Limited

Krunal Shah

Company Secretary & Compliance Officer

Encl.: A/a





"Annexure A"

Sr.	Particulars	Details of Change
No.	T di Godinio	2 Grand Grand Grand
1.	Reason for change. viz. appointment, resignation, removal, death or appointment otherwise	Mr. Gregory John Andrews (DIN: 08904518) appointed as an Additional Director (Non-Executive Non-Independent) of the Company.
		Mr. Gregory John Andrews is a nominee of CA Harbor Investments (part of The Carlyle Group) on the Board of the Company.
2.	Date of appointment/ Cessation	November 6, 2020
3.	Term of appointment	Appointed as an Additional Director (Non-Executive Non-Independent) of the Company w.e.f. November 6, 2020 to hold office until the conclusion of ensuing Annual General Meeting of the Company. His office is liable to retire by rotation.
4.	Brief profile (in case of appointment)	Mr. Greg is a multi-disciplinary executive with 30 years of commercial experience in the pharmaceutical industry. He is a dynamic business leader who creates a positive impact on the business environment through change and active engagement of both internal and external stakeholders.
		Currently, Mr. Greg is a global animal health consultant with offices in the USA and France. He previously held executive positions within three of the major animal health companies where he gained global experience living and working in Australia, Belgium, France and the USA.
		Marketing, communications and management are core disciplines for Mr. Greg. He has led many marketing teams in the USA and Europe and most recently was the Global Marketing Director for Virbac. Mr. Greg headed global



			Public Affairs and Policy for Pfizer Animal Health during its
			IPO transition to Zoetis. He has also held numerous senior
			management roles including country management for
			Belgium and the Netherlands and was Vice President for
			emerging markets in Europe, Africa, Middle East, Russia
			and CIS.
			Mr. Greg received a Bachelor of Science (Hons) from
			Monash University, Australia and Post Graduate Diplomas
			in both Business Management and International Relations
			from the University of Tasmania, Australia.
			·
ŀ	4.	Disclosure of relationships	Mr. Gregory John Andrews does not have any inter-se
		between directors (in case of	relationship with other Directors of the Company.
		appointment of Director)	